Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Recruitment Status: Recruiting
Start Date: February 11, 2019
End Date: January 01, 2021
Inclusion Criteria:
1. Written Informed Consent provided by patient
2. MM, with the following conditions: (CLOSED) *For patients in the Vanguard cohort*
1. Treatment naïve disease with BM clinically indicated *For patients in the RRMM cohort*
1. Relapsed/refractory disease with BM samples clinically indicated
2. Within 4-weeks prior to initiation of 2nd-line or later therapy
3. Patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: Bortezomib (Velcade), Carfilzomib (Kyprolis), Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Cyclophosphamide (Cytoxan), Dexamethasone, Ixazomib (Ninlaro), Venetoclax (Venclexta), Selinexor (Xpovio)
Exclusion Criteria:
1. Unable or unwilling to provide informed consent
2. Daratumumab/Elotuzumab or other antibody-based therapeutic regimens as immediately planned treatment (as prior therapy is acceptable)
3. Patient enrolled/enrolling in a clinical trial where data or specimen sharing provisions preclude use in this study
4. Prior exposure to CAR-T therapy
5. Prior allogeneic stem cell transplant
6. Has received any systemic chemotherapy or RT, including palliative, within 7 days prior to BM biopsy
7. Has received any Ab therapy within 4 weeks prior to BM biopsy
-
Conditions:
- Multiple Myeloma
- Neoplasms, Plasma Cell